Dual Resistance to Maribavir and Ganciclovir in Transplant Recipients
Background: Human cytomegalovirus (CMV) remains an important pathogen, especially for immunocompromised patients such as solid organ and hematopoietic stem cell recipients. Viral genomic mutations conferring drug resistance are an important impediment to effective CMV management and frequently lead...
Saved in:
| Main Author: | Steven B. Kleiboeker |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/17/3/421 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
In Silico Analysis of Mechanisms of Maribavir-Induced Inhibition and Drug Resistance Mutations in pUL97 Kinase Structural Prediction with AlphaFold2
by: Jocelyne Piret, et al.
Published: (2025-07-01) -
Tackling CMV in Transplant Recipients: Past, Present, and Future
by: Tal Schlaeffer-Yosef, et al.
Published: (2025-04-01) -
Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system
by: Haolin Teng, et al.
Published: (2025-05-01) -
Interplay of Belatacept Immunosuppression and Maribavir Antiviral Activity in Recurrent CMV Viremia: Clinical Implications and Literature Review
by: Imran Gani, et al.
Published: (2025-04-01) -
Foscarnet Versus Ganciclovir for Severe Congenital Cytomegalovirus Infection: Short- and Long-Term Follow-Up
by: Giovanni Nigro, et al.
Published: (2025-05-01)